{
    "clinical_study": {
        "@rank": "9870", 
        "arm_group": [
            {
                "arm_group_label": "TAU-284", 
                "arm_group_type": "Experimental", 
                "description": "Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day, once after breakfast and once before bed."
            }, 
            {
                "arm_group_label": "ketotifen fumarate", 
                "arm_group_type": "Active Comparator", 
                "description": "Two TAU-284 5mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day, once after breakfast and once before bed."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to verify the non-inferiority of TAU-284 to ketotifen\n      fumarate dry syrup in the change in the severity of pruritus after the treatment period."
        }, 
        "brief_title": "A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Dermatitis", 
            "Atopic"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, double-blind, parallel-group comparative study to demonstrate the\n      noninferiority of TAU-284 to ketotifen fumarate in pediatric patients with atopic\n      dermatitis, as assessed by the primary endpoint of the change from baseline in pruritus\n      score after 2-week treatment with TAU-284 (20 mg/day) or ketotifen fumarate dry syrup (2\n      g/day); and to investigate the safety, and plasma concentrations of TAU-284."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged between 7 and 15 years\n\n          -  Patients giving assent and whose legal guardian giving informed consent\n\n          -  Outpatients\n\n          -  Patients diagnosed as atopic dermatitis\n\n          -  Patients who require the treatment with topical corticosteroid on areas other than\n             face, head and neck\n\n          -  Patients whose diaries can be properly maintained\n\n          -  Patients who have 2 grades or more pruritus score\n\n        Exclusion Criteria:\n\n          -  Patients with bronchial asthma who require concomitant use of the corticosteroid\n\n          -  Patients who have been undergoing specific desensitization therapy or nonspecific\n             immunomodulation therapy or phototherapy\n\n          -  Patients with current or previous history of drug hypersensitivity\n\n          -  Patients who have been treated with Bepotastine besilate in the past\n\n          -  Patients who have; a skin infection, or with zooparasite such as scabies and\n             pediculosis; eczematous otitis externa with perforation in the eardrum; dermal ulcer,\n             or profound heat burn or frostbite of the severity higher than the grade 2; on areas\n             where topical corticosteroid is applied\n\n          -  Patients who have spastic disease such as epilepsy\n\n          -  Patients who concurrently have renal function abnormalities that may cause safety\n             problems\n\n          -  Patients who do not give consent to use birth control\n\n          -  Pregnant patients, at risk of pregnancy or breastfeeding\n\n          -  Patients who had participated in any clinical trial in the last 12 weeks"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "15 Years", 
            "minimum_age": "7 Years"
        }, 
        "enrollment": {
            "#text": "303", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01840605", 
            "org_study_id": "TAU-284-19"
        }, 
        "intervention": [
            {
                "arm_group_label": "TAU-284", 
                "description": "Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day", 
                "intervention_name": "Bepotastine besilate", 
                "intervention_type": "Drug", 
                "other_name": "TALION 5mg tablets"
            }, 
            {
                "arm_group_label": "ketotifen fumarate", 
                "description": "Two TAU-284 5 mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day", 
                "intervention_name": "ketotifen fumarate", 
                "intervention_type": "Drug", 
                "other_name": "ketotifen fumarate dry syrup"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ketotifen"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hokkaido", 
                    "country": "Japan"
                }, 
                "name": "Medical Corporation Kojinkai Asanuma Dermatology Clinic"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis (Ketotifen Fumarate-controlled, Double-blind, Comparative Study)", 
        "overall_official": {
            "affiliation": "Tokyo Women's Medical University", 
            "last_name": "MAKOTO KAWASHIMA", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in pruritus score", 
            "safety_issue": "No", 
            "time_frame": "baseline and 2 \uff57eeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01840605"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pruritus score", 
                "safety_issue": "No", 
                "time_frame": "2 \uff57eeks"
            }, 
            {
                "measure": "Severity of atopic dermatitis", 
                "safety_issue": "No", 
                "time_frame": "2 \uff57eeks"
            }, 
            {
                "measure": "Patient impression of pruritus", 
                "safety_issue": "No", 
                "time_frame": "2 \uff57eeks"
            }
        ], 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}